Annovis Bio, Inc.
ANVS
Key stats
- Open
- 0.85
- Day high
- 0.90
- Day low
- 0.82
- Previous close
- 0.85
- Volume
- 1.17M
- VWAP
- 0.86
- 52-week high
- 5.50
- 52-week low
- 0.62
- Market cap
- 36.71M
- Shares out
- 43.02M
- Employees
- 7
- Listed
- 2020
About Annovis Bio, Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
PHARMACEUTICAL PREPARATIONS · MALVERN, PA · annovisbio.com
Options · expiring Nov 13
Nov 12, 3:59 PM ET- Call open interest
- 945
- Put open interest
- 132
- Put/call
- 0.14
- At-the-money IV
- 1344.6%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 0.50 call | 0.37 | Nov 12, 2:32 PM | 551 | 824 | — |
| 1 put | 0.10 | Oct 27, 10:48 AM | 100 | 100 | 1948.4% |
| 1 call | 0.14 | Nov 9, 3:16 PM | 36 | 104 | 1344.6% |
| 0.50 put | 0.05 | Nov 9, 1:14 PM | 32 | 32 | 0.0% |
| 1.50 call | 0.05 | Nov 4, 11:34 AM | 1 | 17 | 0.0% |
| 2 call | — | — | 0 | 0 | — |
Quarterly results
Massive · Aug 14, 2026| Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | Q3 2025 to Sep 30, 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| Operating income | −$14.38M | −$18.01M | −$9.71M | −$7.43M |
| Net income | −$14.82M | −$17.61M | −$9.83M | −$7.26M |
| Diluted EPS | -0.40 | -0.63 | -0.38 | -0.37 |
| Operating cash flow | −$21.91M | −$9.01M | −$8.93M | −$3.49M |
| Assets | $22.04M | $16.24M | $21.08M | $17.19M |
| Liabilities | $26.29M | $13.12M | $4.23M | $4.03M |
| Equity | −$4.25M | $3.13M | $16.85M | $13.16M |
Technicals
Massive · Nov 12, 2026- 50-day average1.11
- 200-day average1.82
- RSI (14 days)40.8
Short interest
Massive · Oct 30, 2026- Oct 30, 20265.36M shares · 6.8 days to cover
- Oct 15, 20265.72M shares · 8.3 days to cover
- Sep 30, 20265.90M shares · 6.0 days to cover
- Sep 15, 20266.02M shares · 3.2 days to cover
Related companies
MassiveNews coverage
No stories about Annovis Bio, Inc. right now.